JP2018521075A - エリスロポエチン欠乏症を治療するためのエリスロポエチン及びエリスロポエチン受容体のポジティブアロステリックモジュレーターとしての新規化合物 - Google Patents
エリスロポエチン欠乏症を治療するためのエリスロポエチン及びエリスロポエチン受容体のポジティブアロステリックモジュレーターとしての新規化合物 Download PDFInfo
- Publication number
- JP2018521075A JP2018521075A JP2018503195A JP2018503195A JP2018521075A JP 2018521075 A JP2018521075 A JP 2018521075A JP 2018503195 A JP2018503195 A JP 2018503195A JP 2018503195 A JP2018503195 A JP 2018503195A JP 2018521075 A JP2018521075 A JP 2018521075A
- Authority
- JP
- Japan
- Prior art keywords
- erythropoietin
- compound
- deficiency
- anemia
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000003951 Erythropoietin Human genes 0.000 title claims abstract description 58
- 108090000394 Erythropoietin Proteins 0.000 title claims abstract description 58
- 229940105423 erythropoietin Drugs 0.000 title claims abstract description 58
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 title claims abstract description 55
- 150000001875 compounds Chemical class 0.000 title claims abstract description 36
- 108010075944 Erythropoietin Receptors Proteins 0.000 title claims abstract description 9
- 102100036509 Erythropoietin receptor Human genes 0.000 title claims abstract description 9
- 230000007812 deficiency Effects 0.000 title claims description 25
- 238000011282 treatment Methods 0.000 title claims description 15
- 230000003281 allosteric effect Effects 0.000 title description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 15
- 229940126027 positive allosteric modulator Drugs 0.000 claims abstract description 7
- 208000007502 anemia Diseases 0.000 claims description 28
- 238000000034 method Methods 0.000 claims description 15
- 208000017169 kidney disease Diseases 0.000 claims description 12
- 208000020832 chronic kidney disease Diseases 0.000 claims description 10
- 238000002512 chemotherapy Methods 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 6
- 206010028980 Neoplasm Diseases 0.000 claims description 5
- 201000011510 cancer Diseases 0.000 claims description 5
- 230000004770 neurodegeneration Effects 0.000 claims description 4
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 4
- 206010007558 Cardiac failure chronic Diseases 0.000 claims description 3
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 3
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims description 3
- 206010013774 Dry eye Diseases 0.000 claims description 3
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims description 3
- 206010064930 age-related macular degeneration Diseases 0.000 claims description 3
- 230000032683 aging Effects 0.000 claims description 3
- 206010022437 insomnia Diseases 0.000 claims description 3
- 208000002780 macular degeneration Diseases 0.000 claims description 3
- 230000010437 erythropoiesis Effects 0.000 abstract description 4
- 230000001737 promoting effect Effects 0.000 abstract description 3
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 description 18
- 241000699670 Mus sp. Species 0.000 description 17
- 102000001554 Hemoglobins Human genes 0.000 description 15
- 108010054147 Hemoglobins Proteins 0.000 description 15
- 238000011084 recovery Methods 0.000 description 12
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 229960004316 cisplatin Drugs 0.000 description 10
- 210000002798 bone marrow cell Anatomy 0.000 description 9
- 210000003743 erythrocyte Anatomy 0.000 description 9
- 229930182470 glycoside Natural products 0.000 description 8
- 150000002338 glycosides Chemical class 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 229910052739 hydrogen Inorganic materials 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 229940090044 injection Drugs 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 230000003907 kidney function Effects 0.000 description 4
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 4
- 210000005259 peripheral blood Anatomy 0.000 description 4
- 239000011886 peripheral blood Substances 0.000 description 4
- 230000004224 protection Effects 0.000 description 4
- 230000008085 renal dysfunction Effects 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 208000009304 Acute Kidney Injury Diseases 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 206010021143 Hypoxia Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 208000033626 Renal failure acute Diseases 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 201000011040 acute kidney failure Diseases 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000000747 cardiac effect Effects 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- -1 elixirs Substances 0.000 description 3
- 239000003480 eluent Substances 0.000 description 3
- 230000007954 hypoxia Effects 0.000 description 3
- 208000028867 ischemia Diseases 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 208000001647 Renal Insufficiency Diseases 0.000 description 2
- 206010063897 Renal ischaemia Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 229940109239 creatinine Drugs 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000003394 haemopoietic effect Effects 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 201000006370 kidney failure Diseases 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000002438 mitochondrial effect Effects 0.000 description 2
- 238000003032 molecular docking Methods 0.000 description 2
- 210000004967 non-hematopoietic stem cell Anatomy 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 238000004088 simulation Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- JWVTWJNGILGLAT-UHFFFAOYSA-N 1-ethenyl-4-fluorobenzene Chemical compound FC1=CC=C(C=C)C=C1 JWVTWJNGILGLAT-UHFFFAOYSA-N 0.000 description 1
- UAJRSHJHFRVGMG-UHFFFAOYSA-N 1-ethenyl-4-methoxybenzene Chemical compound COC1=CC=C(C=C)C=C1 UAJRSHJHFRVGMG-UHFFFAOYSA-N 0.000 description 1
- DDGDLIFRYYVSJT-UHFFFAOYSA-N 2-bromo-4,6-dimethoxyphenol Chemical compound COC1=CC(Br)=C(O)C(OC)=C1 DDGDLIFRYYVSJT-UHFFFAOYSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- NBYKNHXYUNZKLY-WYRLRVFGSA-N Br[C@@]1(O)[C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO.CC(=O)C Chemical compound Br[C@@]1(O)[C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO.CC(=O)C NBYKNHXYUNZKLY-WYRLRVFGSA-N 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 206010049466 Erythroblastosis Diseases 0.000 description 1
- 208000031206 Familial polycythaemia Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 101000987586 Homo sapiens Eosinophil peroxidase Proteins 0.000 description 1
- 101001123331 Homo sapiens Peroxisome proliferator-activated receptor gamma coactivator 1-alpha Proteins 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010022971 Iron Deficiencies Diseases 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 1
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 1
- 102100028960 Peroxisome proliferator-activated receptor gamma coactivator 1-alpha Human genes 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 206010061481 Renal injury Diseases 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000001435 Thromboembolism Diseases 0.000 description 1
- 238000010162 Tukey test Methods 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 208000012998 acute renal failure Diseases 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 208000015322 bone marrow disease Diseases 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000011748 cell maturation Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229920001429 chelating resin Polymers 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
- 229940105442 cisplatin injection Drugs 0.000 description 1
- 230000003081 coactivator Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000007398 colorimetric assay Methods 0.000 description 1
- 238000005094 computer simulation Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000000267 erythroid cell Anatomy 0.000 description 1
- 210000003013 erythroid precursor cell Anatomy 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 210000002149 gonad Anatomy 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 150000003278 haem Chemical group 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 208000007475 hemolytic anemia Diseases 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 102000044890 human EPO Human genes 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 208000037906 ischaemic injury Diseases 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 208000037806 kidney injury Diseases 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000011418 maintenance treatment Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000003098 myoblast Anatomy 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 230000003589 nefrotoxic effect Effects 0.000 description 1
- 231100000381 nephrotoxic Toxicity 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000004112 neuroprotection Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 239000008203 oral pharmaceutical composition Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 238000006213 oxygenation reaction Methods 0.000 description 1
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- JOVOSQBPPZZESK-UHFFFAOYSA-N phenylhydrazine hydrochloride Chemical compound Cl.NNC1=CC=CC=C1 JOVOSQBPPZZESK-UHFFFAOYSA-N 0.000 description 1
- 229940038531 phenylhydrazine hydrochloride Drugs 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 208000037244 polycythemia vera Diseases 0.000 description 1
- 239000008389 polyethoxylated castor oil Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 201000006870 primary polycythemia Diseases 0.000 description 1
- 230000009979 protective mechanism Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000001084 renoprotective effect Effects 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000000287 tissue oxygenation Effects 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Substances C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 1
- 229960002555 zidovudine Drugs 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Ophthalmology & Optometry (AREA)
- Cardiology (AREA)
- Anesthesiology (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Epidemiology (AREA)
- Saccharide Compounds (AREA)
Abstract
Description
EH202類似体のEPO-EPO受容体(EPOR)複合体への結合を予測するためにコンピュータードッキングシミュレーションが実施された。コンピューターシミュレーションシステムのモデルにドッキングされた、発明者らにより設計された200を超える化学分子の中から、EPO-EPOR複合体への結合の自由エネルギーにより、33の化学分子がポジティブアロステリックモジュレーター(EH202〜EH234)として選択された。各EH202類似体がEPOフリーナイーブEPORよりもEPO結合EPOR複合体(EPO/EPOR)に優先的に結合することが分かった(EH202類似体の結合自由エネルギーは-6.92〜-10.03 kcal・mol-1、対してEPOフリーナイーブEPORは-6.30 kcal・mol-1と推定される)。下の表2に示す。
実施例2に記載した手順に従った。産物の収率は98%であった。
国家実験動物センター(NLAC、台湾)より購入した8〜10週齢のC57BL/6JNarlマウスが使用された。急性溶血性貧血が、リン酸緩衝生理食塩水(PBS)中のフェニルヒドラジン塩酸塩(Sigma−Aldrich)単回腹腔内(i.p.)注射(投与量100mg/kg)で誘発された。マウスからの骨髄細胞が単離され、注射6日後の若干の変更で前述の方法のとおりに培養された(Worthington et al.、1985及びRosenthal et al.、1987)。細胞は1%(v/v)牛血清アルブミン(BSA、Sigma−Aldrich)、7.5μMの2-メルカプトエタノール(Sigma−Aldrich)、1.4mMのL−グルタミン(Sigma−Aldrich)、10μMの塩化鉄(FeCl3、Sigma−Aldrich)、50mU/mlのEPO(RecormonEpoetin、Roche)を含有するMEM α培地(α−MEM、Gibco)で約6×105細胞/mlに調整され、96ウェルプレート(Costar)に約1.5×105細胞/ウェルで播かれた後、37℃で5%CO2-95%空気の加湿型インキュベータで培養された。細胞は異なる濃度のEH202〜EH207、EH222、EH232(0、0.1、1、10、選択的に100μg/ml)で翌日処理され、ヘモグロビンの相対レベルがDAFベースのヘモグロビン比色定量アッセイ(Kaihoand Mizuno、1985及びWorthington et al.、1985)で4日後の若干の変更で判定された。簡単に説明すると、細胞はPBSで洗浄され、0.01%(v/v)Nonidet(商標) P40(NP-40、Sigma−Aldrich)の50μl/ウェルで溶解され、100μg/mlの4,5-ジアミノフルオレセイン(DAF、Sigma−Aldrich)100μl/ウェルと30%過酸化水素(Sigma−Aldrich)6μl/ウェルが添加された。5〜10分間のインキュベーション後、620nmでの吸光度がVictor 2 1420マルチラベルカウンター(Wallac、PerkinElmer)で測定された。結果は相対指数±S.E.(n=6)で表され、統計的有意性がスチューデントのT検定で評価された(*P<0.05、**P<0.01、***P<0.001、対照群(0μg/ml)と比較)。結果によれば、化合物は濃度0.1〜100μg/mlでヘモグロビンの形成を有意に促進することが示された(図1A〜1G)。
6〜7週齢のC57Bl/6Jオスマウス40匹に腹腔内(i.p.)注射で3用量のシスプラチン(Sigma−Aldrich)が7、6、6 mg・kg−1体重のスキームに従い、4〜5日間隔で投与され、正常群(n=4)には生理食塩水が注射された(図1のスキーム)。12日目に、採取された血清試料の尿素窒素含量(BUN)が測定された。BUN値が80mg・dL−1を超えるマウスが実験に選択された。平均70%の注射マウスに腎障害が誘発され、無効なマウスはEH202治療実験から除外された。その後マウスはさらに2週間、対照群(Ctrl、n=6)と3つのEH202治療群(各群n=5〜6)を含む4つのコホートに無作為に分けられた。全マウスから血液試料が5日ごとに採取された。Sysmex Kx-21血液分析器(Sysmex America)を使用して全血球計算値からRBC数が判定され、血清BUN値とクレアチニン値が市販のキット(Randox Laboratories Ltd. 英国)を使用して測定された。結果はすべて平均±SEMとして表されている。スチューデントT検定を使用して統計分析が実施された。One−way ANOVAを使用して動物実験群間の違いが調べられた。実験群の平均間のポストホック差がテューキーの検定で判定された。P<0.05が有意と見なされた。
急性腎傷害は腎毒性薬物の使用により引き起こされる腎虚血に起因することがあるため、腎不全の貧血に対するEH202誘発EPO産生の効果を判定するために、樹立されたシスプラチン誘発腎障害マウスモデルを採用した(図2A)。初回シスプラチン注射後12日目からの顕著な腎機能障害と19日目からの貧血が観察された。注目すべきは、10日間にわたる30及び90mg・kg-1のEH202の投与(24日目、図2B)がほぼ完全な腎障害の回復につながったことである。さらに、EH202の10、30、90mg・kg-1治療群のBUN値も顕著に回復した(図2C)。また、30及び90mg・kg-1のEH202投与(図2Dと図2E)は貧血の回復を増加した。まとめると、これらの発見はEH202がシスプラチン誘発貧血と腎障害からの回復を向上したことを示唆している。
Claims (15)
- エリスロポエチン及びエリスロポエチン受容体のポジティブアロステリックモジュレーターとして作用することで、エリスロポエチン欠乏症の治療に使用されることを特徴とする、請求項1に記載の化合物。
- エリスロポエチン及びエリスロポエチン受容体のポジティブアロステリックモジュレーターとして作用することで、エリスロポエチン欠乏症の治療に使用されることを特徴とする、請求項2に記載の化合物。
- 請求項1に記載の化合物と、薬学的に許容可能な担体を含むことを特徴とする、医薬組成物。
- エリスロポエチン欠乏症の治療に使用されることを特徴とする、請求項5に記載の医薬組成物。
- 前記エリスロポエチン欠乏症が、貧血症、慢性腎疾患、慢性心不全、神経変性疾患、加齢性黄斑変性症、慢性閉塞性肺疾患、化学療法を受けている患者における貧血がん、ドライアイ、加齢に伴う不眠症で構成される群より選択されることを特徴とする、請求項7に記載の医薬組成物。
- 前記エリスロポエチン欠乏症が貧血症であることを特徴とする、請求項8に記載の医薬組成物。
- 前記エリスロポエチン欠乏症が腎疾患に関連する貧血症であることを特徴とする、請求項9に記載の医薬組成物。
- 必要とする被験者に対し、請求項1に記載の化合物の有効量を投与する工程を含むことを特徴とする、エリスロポエチン欠乏症の治療方法。
- 前記エリスロポエチン欠乏症が、貧血症、慢性腎疾患、慢性心不全、神経変性疾患、加齢性黄斑変性症、慢性閉塞性肺疾患、化学療法を受けている患者における貧血がん、ドライアイ、加齢に伴う不眠症で構成される群より選択されることを特徴とする、請求項11に記載のエリスロポエチン欠乏症の治療方法。
- 前記エリスロポエチン欠乏症が貧血症であることを特徴とする、請求項13に記載のエリスロポエチン欠乏症の治療方法。
- 前記エリスロポエチン欠乏症が腎疾患に関連する貧血症であることを特徴とする、請求項14に記載のエリスロポエチン欠乏症の治療方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562195916P | 2015-07-23 | 2015-07-23 | |
US62/195,916 | 2015-07-23 | ||
PCT/CN2016/000413 WO2017012289A1 (en) | 2015-07-23 | 2016-07-25 | New compounds as positive allosteric modulators for erythropoietin and erythropoietin receptor to treat erythropoietin deficiency diseases |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2018521075A true JP2018521075A (ja) | 2018-08-02 |
JP2018521075A5 JP2018521075A5 (ja) | 2019-07-18 |
JP6796127B2 JP6796127B2 (ja) | 2020-12-02 |
Family
ID=57833739
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018503195A Active JP6796127B2 (ja) | 2015-07-23 | 2016-07-25 | エリスロポエチン欠乏症を治療するためのエリスロポエチン及びエリスロポエチン受容体のポジティブアロステリックモジュレーターとしての新規化合物 |
Country Status (9)
Country | Link |
---|---|
US (1) | US10040813B2 (ja) |
EP (1) | EP3337811B1 (ja) |
JP (1) | JP6796127B2 (ja) |
KR (1) | KR102585473B1 (ja) |
CN (1) | CN107922453B (ja) |
AU (1) | AU2016297417B2 (ja) |
CA (1) | CA2991446C (ja) |
TW (1) | TWI649328B (ja) |
WO (1) | WO2017012289A1 (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10695402B2 (en) | 2017-03-16 | 2020-06-30 | University Of Rochester | Erythropoietin for gastrointestinal dysfunction |
WO2022159414A1 (en) | 2021-01-22 | 2022-07-28 | University Of Rochester | Erythropoietin for gastroinfestinal dysfunction |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8980954B2 (en) * | 2006-04-25 | 2015-03-17 | Stc.Unm | Substituted cis- and trans-stilbenes as therapeutic agents |
CN101161245B (zh) * | 2007-11-29 | 2011-11-09 | 首都医科大学宣武医院 | 二苯乙烯苷及其衍生物抑制突触核蛋白过度表达的用途 |
US20100160243A1 (en) * | 2008-12-24 | 2010-06-24 | National Yang-Ming University | Compounds and methods for enhancing erythropoiesis |
CN103156868A (zh) * | 2011-12-09 | 2013-06-19 | 天津市国际生物医药联合研究院 | 二苯乙烯苷类化合物在治疗和预防艾滋病中的用途 |
CN105188688A (zh) * | 2013-03-28 | 2015-12-23 | 吴淑芬 | 用于在非造血性细胞中诱导促红细胞生成素(epo)介导的产生血红蛋白表达和线粒体生物合成的组合物和方法 |
CN104586865B (zh) * | 2013-10-31 | 2017-08-08 | 昆药集团股份有限公司 | 一种治疗心血管疾病的药物组合物 |
-
2016
- 2016-07-25 US US15/218,784 patent/US10040813B2/en active Active
- 2016-07-25 WO PCT/CN2016/000413 patent/WO2017012289A1/en active Application Filing
- 2016-07-25 CN CN201680035295.3A patent/CN107922453B/zh active Active
- 2016-07-25 EP EP16826986.8A patent/EP3337811B1/en active Active
- 2016-07-25 KR KR1020187002135A patent/KR102585473B1/ko active IP Right Grant
- 2016-07-25 AU AU2016297417A patent/AU2016297417B2/en active Active
- 2016-07-25 TW TW105123496A patent/TWI649328B/zh active
- 2016-07-25 JP JP2018503195A patent/JP6796127B2/ja active Active
- 2016-07-25 CA CA2991446A patent/CA2991446C/en active Active
Also Published As
Publication number | Publication date |
---|---|
TW201716423A (zh) | 2017-05-16 |
CA2991446C (en) | 2023-09-26 |
KR20180030844A (ko) | 2018-03-26 |
EP3337811A1 (en) | 2018-06-27 |
CA2991446A1 (en) | 2017-01-26 |
AU2016297417A1 (en) | 2018-01-25 |
KR102585473B1 (ko) | 2023-10-05 |
TWI649328B (zh) | 2019-02-01 |
EP3337811B1 (en) | 2020-05-20 |
EP3337811A4 (en) | 2019-03-13 |
WO2017012289A1 (en) | 2017-01-26 |
AU2016297417B2 (en) | 2021-01-28 |
US10040813B2 (en) | 2018-08-07 |
CN107922453B (zh) | 2021-05-25 |
CN107922453A (zh) | 2018-04-17 |
JP6796127B2 (ja) | 2020-12-02 |
US20170027970A1 (en) | 2017-02-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5856659B2 (ja) | 赤血球生成の強化に係わる化合物とその方法 | |
WO2017059204A1 (en) | Azolylacryloyl derivatives as therapeutic agents for sickle cell disease | |
CA2907965C (en) | Composition and use for treating cardiac failure | |
JP6796127B2 (ja) | エリスロポエチン欠乏症を治療するためのエリスロポエチン及びエリスロポエチン受容体のポジティブアロステリックモジュレーターとしての新規化合物 | |
US11878997B2 (en) | Methods of treatment comprising Selenoprotein P fragment-containing compounds | |
ES2800162T3 (es) | Uso terapéutico de moduladores funcionales negativos de la eritropoyetina | |
PT100756B (pt) | Novos derivados de gangliosidos, processo para a sua preparacao e composicoes farmaceuticas que os contem | |
WO2020249120A9 (zh) | 氨基硫醇类化合物作为脑神经或心脏保护剂的用途 | |
EP4241837A2 (en) | Nicotinamide mononucleotide derivatives in the treatment and prevention of sickle cell disease | |
US20230255961A1 (en) | Rotomeric Isomers of 4-Alkyl-5-Heteroaryl-3H-1,2-Dithiole-3-Thiones | |
CN107674051B (zh) | 4-羟基他莫昔酚环状衍生物乏氧活化前药及其药物用途 | |
WO2021173476A1 (en) | Compounds, pharmaceutical formulations, and methods for treatment of cancer | |
AU2013201714B2 (en) | Compounds and methods for enhancing erythropoiesis | |
ITTO20091020A1 (it) | "cardiomyocytes anti-apoptotic molecules, products and compositions thereof" |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190617 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190617 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200519 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20200812 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20201012 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20201104 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20201113 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6796127 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |